Amicus Therapeutics (FOLD) : Traders are bullish on Amicus Therapeutics (FOLD) as it has outperformed the S&P 500 by a wide margin of 16.55% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.18%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.15% in the last 1 week, and is up 17% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Amicus Therapeutics, Inc. is up 2.63% in the last 3-month period. Year-to-Date the stock performance stands at -27.63%. The stock has recorded a 20-day Moving Average of 4.72% and the 50-Day Moving Average is 13.54%.
Amicus Therapeutics (NASDAQ:FOLD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $7.00 and $6.92 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $7.17. The buying momentum continued till the end and the stock did not give up its gains. It closed at $7.02, notching a gain of 0.14% for the day. The total traded volume was 1,030,350 . The stock had closed at $7.01 on the previous day.
Also, Bank of America initiates coverage on Amicus Therapeutics (NASDAQ:FOLD) The current rating of the shares is Buy. Equity Analysts at the Firm announces the price target to $10 per share. The rating by the firm was issued on May 18, 2016.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.